Sequence information
Variant position: 1081 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: 1603 The length of the canonical sequence.
Location on the sequence:
VHGGKSSAQSAESSSVAMTP
T YMDSPRKDGAFFMEFVRSPR
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: The multiple alignment of the region surrounding the variant against various orthologous sequences.
Human VHGGKSSAQSAESSSVAMTPT YMDSPRKDGAFFMEFVRSPR
Mouse VHG-KSSTQPAENSSVAMTPT YVDSPRKDGAFFMEFVRSPR
Sequence annotation in neighborhood: The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:Type: the type of sequence feature. Positions: endpoints of the sequence feature. Description: contains additional information about the feature.
Type Positions Description
Chain
1 – 1603
GATOR complex protein DEPDC5
Alternative sequence
560 – 1603
Missing. In isoform 2.
Mutagenesis
1065 – 1065
K -> R. No effect on ubiquitination. Loss of interaction with KLHL22 and ubiquitination; when associated with R-447, R-710, R-1088 and R-1574.
Mutagenesis
1088 – 1088
K -> R. No effect on ubiquitination. Loss of interaction with KLHL22 and ubiquitination; when associated with R-447, R-710, R-1065 and R-1574.
Literature citations
Mutations in the mammalian target of rapamycin pathway regulators NPRL2 and NPRL3 cause focal epilepsy.
Ricos M.G.; Hodgson B.L.; Pippucci T.; Saidin A.; Ong Y.S.; Heron S.E.; Licchetta L.; Bisulli F.; Bayly M.A.; Hughes J.; Baldassari S.; Palombo F.; Santucci M.; Meletti S.; Berkovic S.F.; Rubboli G.; Thomas P.Q.; Scheffer I.E.; Tinuper P.; Geoghegan J.; Schreiber A.W.; Dibbens L.M.;
Ann. Neurol. 79:120-131(2016)
Cited for: INVOLVEMENT IN FFEVF1; VARIANTS FFEVF1 ASP-214; PRO-542; PRO-1081; PHE-1154 AND GLN-1268;
Disclaimer:
Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.